Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Partially Remote

Drugs

Locations

Clinical Specialty

421-440 of 998 trials

Heart Failure: Finerenone Study

We are testing the medication finerenone for patients with heart failure who cannot tolerate standard treatments. The study aims to see if it is safe and effective for these individuals.

Heart Failure>2 yearsConfirmation phase (III)≤5 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncologyPulmonology

Medical Cannabis Aerosol for Diabetic Peripheral Neuropathic Pain

We are studying whether a medical cannabis aerosol can help reduce pain for people with diabetic peripheral neuropathic pain. Participants will compare different doses of THC to a placebo to assess pain relief and quality of life.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)Investigational Medicines Cost Reimbursement Partially RemoteEndocrinologyNeurology

Eosinophilic Esophagitis: BP1.7881 Treatment Study

We are testing a new medication, BP1.7881, for adults with eosinophilic esophagitis to see if it can improve their condition. The study will also look at how safe and well-tolerated the treatment is.

Eosinophilic Esophagitis3-6 monthsEfficacy phase (II)≤5 visits Partially RemoteAllergologyGastroenterology

Hidradenitis Suppurativa: Secukinumab Treatment Study

We are investigating the long-term effects of secukinumab on people with moderate to severe hidradenitis suppurativa. This study will help us understand its safety and effectiveness compared to a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

Autoimmune Disease: Ianalumab Delivery Methods

We are comparing two ways to deliver ianalumab to adults with autoimmune diseases. This study will help us understand how well the medication works and its safety when given in different forms.

Sjögren's DiseaseRheumatoid ArthritisSystemic Lupus Erythematosus6-12 monthsEfficacy phase (II)No Placebo Investigational Medicines Partially RemoteInternal MedicineRheumatology

Pancreatic Cancer: Antiplatelet Therapy Study

We are investigating if adding an antiplatelet medication to standard care can help prevent blood clots in patients with pancreatic cancer. We also want to see if it may improve survival rates.

Pancreatic Ductal Cancer6-12 monthsConfirmation phase (III)6-10 visits No Placebo Standard Medicines Partially RemoteCardiologyOncology

Idiopathic Pulmonary Fibrosis: Buloxibutid Study

We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.

Idiopathic Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Lung Cancer: Repotrectinib for Elderly Patients

We are studying the effectiveness of Repotrectinib in frail or elderly patients with advanced lung cancer. The trial aims to see if this treatment can improve tumor response and overall health.

Stage III/IV Non-Small-Cell Lung Cancer with ROS1 Rearrangement>2 yearsEfficacy phase (II)≤5 visits No Placebo Standard Medicines Partially RemoteOncologyPulmonology

Atopic Dermatitis in Children: Abrocitinib Study

We are investigating the effectiveness and safety of Abrocitinib for children aged 6 to under 12 with moderate-to-severe atopic dermatitis. The study will compare it to a placebo while using other topical treatments.

Moderate-to-Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Partially RemoteAllergologyDermatology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteCardiology

Systemic Lupus Erythematosus: Belimumab Study

We are studying the effects of belimumab in adults with early systemic lupus erythematosus to see if it helps improve their condition and reduce steroid use.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)16-20 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteRheumatology

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal Medicine

Hand Osteoarthritis: Metformin Treatment

We are investigating whether metformin can reduce finger joint pain in people with hand osteoarthritis. This study compares its effects to a placebo over 16 weeks.

Hand Osteoarthritis3-6 monthsConfirmation phase (III)6-10 visits Standard Medicines Partially RemoteInternal MedicineRheumatology

Heart Attack Treatment: RTP-026 Study

We are exploring a new medication, RTP-026, for patients who have had a heart attack. The study will assess its safety and effectiveness compared to a placebo.

Heart Attack (Acute Myocardial Infarction)1-2 yearsEfficacy phase (II)6-10 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteEndocrinologyOphthalmology

Thyroid Eye Disease: Efgartigimod PH20 SC Study

We are testing a new treatment called efgartigimod PH20 SC in adults with thyroid eye disease. The goal is to see if it works better than a placebo in reducing symptoms.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteEndocrinologyOphthalmology

MOG Antibody-Associated Disease: Rozanolixizumab Study

We are studying whether Rozanolixizumab is effective and safe for adults with MOG antibody-associated disease. This research aims to provide insights into a potential new treatment for this condition.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteNeurology

Asthma Treatment: Atuliflapon Study

We are investigating whether Atuliflapon can improve symptoms in adults with moderate to severe uncontrolled asthma. This study compares its effects to a placebo to ensure safety and efficacy.

Moderate-to-Severe Uncontrolled Asthma3-6 monthsEfficacy phase (II)6-10 visits Investigational Medicines Cost Reimbursement Partially RemoteAllergologyPulmonology

Alpha-1 Antitrypsin Deficiency: BEAM-302 Treatment Study

We are exploring a new treatment for adults with Alpha-1 Antitrypsin Deficiency-related lung or liver disease. The study aims to evaluate its safety and effectiveness in improving health outcomes.

Alpha-1 Antitrypsin Deficiency (AATD)>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteHepatologyPulmonology

Search Clinical Trials in the European Union